BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 17433425)

  • 1. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
    Gulubova M; Manolova I; Kyurkchiev D; Julianov A; Altunkova I
    APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
    Yuen MF; Norris S
    Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
    Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
    Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of CD4+ cells expressing CD161 in cancer patients.
    Iliopoulou EG; Karamouzis MV; Missitzis I; Ardavanis A; Sotiriadou NN; Baxevanis CN; Rigatos G; Papamichail M; Perez SA
    Clin Cancer Res; 2006 Dec; 12(23):6901-9. PubMed ID: 17145807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
    Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
    Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
    Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
    Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications.
    Ferrandina G; Pierelli L; Perillo A; Rutella S; Ludovisi M; Leone G; Mancuso S; Scambia G
    Clin Cancer Res; 2003 Jan; 9(1):195-200. PubMed ID: 12538469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between the percent of CD3- CD56+ cells and NK precursor function.
    Gharehbaghian A; Donaldson C; Newman J; Bannister G; Bradley BA
    Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):167-75. PubMed ID: 17237569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age.
    Simone R; Zicca A; Saverino D
    J Leukoc Biol; 2008 Dec; 84(6):1454-61. PubMed ID: 18780874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
    Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
    Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma.
    Li X; Ye DF; Xie X; Chen HZ; Lu WG
    Cancer Invest; 2005; 23(5):399-403. PubMed ID: 16193639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
    Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Ichihara F; Kono K; Takahashi A; Kawaida H; Sugai H; Fujii H
    Clin Cancer Res; 2003 Oct; 9(12):4404-8. PubMed ID: 14555512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
    Liu M; Xie J; Zhao S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.